课题基金 / 基金详情

131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA

131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA
80MCI/M2 剂量的 131I-LYM-1 治疗难治性 B 细胞淋巴瘤
批准号：
6113991
负责人：
RICHARD T SILVER
金额：
$5.82万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6113991
关键词：
B lymphocyte clinical research clinical trials drug adverse effect human subject human therapy evaluation iodine neoplasm /cancer radionuclide therapy nonHodgkin's lymphoma radiation therapy dosage radionuclides

项目摘要

项目成果

RICHARD T SILVER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a clinical trial to determine the effectiveness of I-131-LYM-1 as salvage therapy in eliminating or reducing detectable tumor in subjects with intermediate to high-grade non-Hodgkin's lymphoma who are refractory to current first-line or salvage chemotherapy and to evaluate the safety of systemically administered I-131-LYM-1 in terms of the incidence of adverse reactions and toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STEM CELL RESCUE AFTER BONE MARROW CURETTAGE FOR TREATMENT OF AMM
131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA
131I-LYM-1 AT A DOSE OF 80MCI/M2 IN THE TREATMENT OF REFRACTORY B-CELL LYMPHOMA
CANCER AND LEUKEMIA GROUP B
海外基金